Similar articles

• 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.

  Odibo AO, Stamilio DM, Macones GA, Polsky D. Odibo AO, et al. Obstet Gynecol. 2006 Sep;108(3 Pt 1):492-9. doi: 10.1097/01.AOG.0000232503.92206.d8. Obstet Gynecol. 2006. PMID: 16946206
• Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials.

  Thangaratinam S, Coomarasamy A. Thangaratinam S, et al. Obstet Gynecol. 2005 Jun;105(6):1483-4; author reply 1484. doi: 10.1097/01.AOG.0000164476.19404.6e. Obstet Gynecol. 2005. PMID: 15932848 No abstract available.
• What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?

  Hall NR. Hall NR. Obstet Gynecol Clin North Am. 2011 Jun;38(2):235-46, ix-x. doi: 10.1016/j.ogc.2011.02.014. Obstet Gynecol Clin North Am. 2011. PMID: 21575799 Review.
• Safety signals of 17-OHP-C use in pregnancy and efficacy in the prevention of preterm birth.

  Calda P. Calda P. J Matern Fetal Neonatal Med. 2009 Jun;22(6):540-2. doi: 10.1080/14767050802556042. J Matern Fetal Neonatal Med. 2009. PMID: 19089768 No abstract available.
• Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.

  Bailit JL, Votruba ME. Bailit JL, et al. Am J Obstet Gynecol. 2007 Mar;196(3):219.e1-7. doi: 10.1016/j.ajog.2006.12.021. Am J Obstet Gynecol. 2007. PMID: 17346527 Review.